Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen

The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid levels and blood pressure (BP) were assessed in transgender persons. In this prospective, observational substudy of the European Network for the Investigation of Gender...